Skip to main content

Table 4 Febrile neutropenia risk of CT regimen and additional risk factors per EORTC guidelines (analysis population)

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

 

Breast (n = 356)

Lung (n = 280)

GI: colorectal (n = 103)

GI: non-colorectal (n = 72)

GYN: ovarian (n = 72)

GYN: non-ovarian (n = 39)

Head & neck (n = 105)

Prostate (n = 66)

Other (n = 81)

Total (n = 1174)

Patients with CT regimen in EORTC FN risk category, n (%)

 Low (< 10%)

0 (0)

15 (5.4)

0 (0)

0 (0)

28 (38.9)

0 (0)

1 (1)

0 (0)

12 (14.8)

56 (4.8)

 Intermediate (10–20%)

253 (71.1)

139 (49.6)

43 (41.7)

30 (41.7)

2 (2.8)

0 (0)

5 (4.8)

40 (60.6)

1 (1.2)

513 (43.7)

 High (≥ 20%)

12 (3.4)

30 (10.7)

0 (0)

1 (1.4)

2 (2.8)

0 (0)

0 (0)

0 (0)

20 (24.7)

65 (5.5)

 Unknown

91 (25.6)

96 (34.3)

60 (58.3)

41 (56.9)

40 (55.6)

39 (100)

99 (94.3)

26 (39.4)

48 (59.3)

540 (46.0)

Patients with patient-related EORTC risk factor, n (%)

 Age > 65 years

94 (26.4)

120 (42.9)

52 (50.5)

34 (47.2)

42 (58.3)

24 (61.5)

32 (30.5)

53 (80.3)

38 (46.9)

489 (41.7)

 Female gender

351 (98.6)

87 (31.1)

45 (43.7)

26 (36.1)

72 (100)

39 (100)

15 (14.3)

0 (0)

12 (14.8)

647 (55.1)

 Advanced tumour: stage III or IV

199 (55.9)

265 (94.6)

102 (99.0)

66 (91.7)

65 (90.3)

34 (87.2)

90 (85.7)

65 (98.5)

75 (92.6)

961 (81.9)

 ECOG PS ≥ 2*

34 (9.6)

74 (26.7)

8 (8.0)

21 (29.6)

16 (23.5)

4 (11.1)

14 (13.5)

22 (34.4)

20 (25.3)

213 (18.5)

 Haemoglobin level < 12 g/dL*

88 (27.7)

120 (44.8)

44 (44.0)

39 (56.5)

43 (64.2)

25 (67.6)

31 (36.0)

38 (62.3)

42 (53.2)

470 (43.3)

 Prior episode of FN

11 (3.1)

10 (3.6)

3 (2.9)

5 (6.9)

2 (2.8)

0 (0)

1 (1.0)

2 (3.0)

5 (6.2)

39 (3.3)

 Concomitant pathologies with increased risk

11 (3.1)

56 (20.0)

5 (4.9)

4 (5.6)

4 (5.6)

4 (10.3)

9 (8.6)

9 (13.6)

19 (23.5)

121 (10.3)

 No G-CSF use before inclusion

318 (89.3)

270 (96.4)

90 (87.4)

68 (94.4)

64 (88.9)

34 (87.2)

99 (94.3)

60 (90.9)

72 (88.9)

1075 (91.6)

  1. *Some patients had missing data
  2. Liver, renal or cardiovascular disease, according to EORTC definition
  3. Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, and multiple independent sites
  4. CT chemotherapy, ECOG PS Eastern Cooperative Oncology Group Performance Status, EORTC European Organisation for Research and Treatment of Cancer, FN febrile neutropenia, G-CSF, granulocyte colony-stimulating factor, GI gastrointestinal, GYN gynaecological, ST solid tumour